An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Linifanib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms LiGHT
- Sponsors Abbott Laboratories
- 26 Jan 2013 Results presented at the 2013 European Multidisciplinary Cancer Congress.
- 26 Jan 2013 Primary endpoint 'Overall-survival-duration' has not been met.
- 31 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History